{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:58:53Z","timestamp":1789707533966,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pneumonia"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Randomized Controlled Trials (RCTs) assessing adjuvant corticosteroids for hospitalized Community-Acquired Pneumonia (CAP) show mixed results, suggesting Heterogeneity of Treatment Effect (HTE). Current guidelines conflict: some restrict use to septic shock, while others advocate for broader application in severe CAP. Among three recent, large RCTs focused on severe CAP, however, only one demonstrated significant benefit, raising the question: should severity-based treatment guidance really be preferred?. The debate surrounding corticosteroid use in CAP is complicated by two issues: the lack of a unified definition for \u2018severe CAP\u2019, with definitions either based on the American Thoracic Society criteria or severity scores like the Pneumonia Severity Index, and the reliance on Aggregate Data Meta-Analyses (ADMAs). ADMAs synthesize trial results by categorizing entire RCTs as severe or non-severe, while most RCT populations included patients with varying disease severities. Individual Patient Data Meta-Analyses (IPDMAs) enable stratification on a patient-level. Our recent IPDMA utilized multivariate predictive HTE modelling in six RCT datasets to identify patient characteristics predicting corticosteroid benefit, which suggested C-reactive protein (CRP) as a predictor of benefit. Therefore, this finding was externally validated in two other RCTs, revealing statistically significant HTE found across baseline CRP subgroups (i.e., \u2264\u2009204\u00a0mg\/L vs. &gt;204\u00a0mg\/L), while no such HTE was found across severity-based subgroups. These findings may advocate for corticosteroid treatment guided by CRP instead of disease severity. CRP, however, is unlikely the sole driver of corticosteroids benefit, as other potential sources of HTE like imaging or cytokines (\u2018known unknowns\u2019) or other unmeasured variables (\u2018 unknown unknowns\u2019) may exist, and moreover, our IPDMA post-hoc suggested HTE across aetiology and treatment timing. Moving forward, the efficacy of precision medicine in CAP hinges on rigorous replication of HTE findings \u2014being notoriously susceptible to false positives\u2014 in independent datasets, and harmonized and standardized data collection in future trials. Based on current evidence, CRP may serve as a pragmatic tool to guide corticosteroid treatment, but given to the drug\u2019s \u201cpendulum swings\u201d from broad use to avoidance over the last decades, caution remains essential.<\/jats:p>","DOI":"10.1186\/s41479-026-00198-y","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:01:37Z","timestamp":1777071697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The heterogeneous treatment effect of adjuvant therapy with corticosteroids in patients with Community-Acquired Pneumonia: a review"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3716-1863","authenticated-orcid":false,"given":"Jim. M.","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse H.","family":"Krijthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Martin-Loeches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"198_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.7326\/M18-3667","volume":"172","author":"DM Kent","year":"2020","unstructured":"Kent DM, Paulus JK, Van Klaveren D, et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann Intern Med. 2020;172:35\u201345.","journal-title":"Ann Intern Med"},{"key":"198_CR2","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1001\/jama.2021.20552","volume":"326","author":"DC Angus","year":"2021","unstructured":"Angus DC, Chang C-CH. Heterogeneity of treatment effect: estimating how the effects of interventions vary across individuals. JAMA. 2021;326:2312\u20133.","journal-title":"JAMA"},{"key":"198_CR3","doi-asserted-by":"crossref","unstructured":"Bergmann F, Pracher L, Sawodny R, et al. Efficacy and safety of corticosteroid therapy for community-acquired pneumonia: a meta-analysis and meta-regression of randomized controlled trials. Clin Infect Dis. 2023;ciad496.","DOI":"10.1093\/cid\/ciad496"},{"key":"198_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-2600(24)00405-3","volume":"13","author":"JM Smit","year":"2025","unstructured":"Smit JM, Van Der Zee PA, Stoof SCM, et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials. Lancet Respir Med. 2025;13:221\u201333.","journal-title":"Lancet Respir Med"},{"key":"198_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","volume":"49","author":"I Martin-Loeches","year":"2023","unstructured":"Martin-Loeches I, Torres A, Nagavci B, et al. ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49:615\u201332.","journal-title":"Intensive Care Med"},{"key":"198_CR6","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1097\/CCM.0000000000006172","volume":"52","author":"D Chaudhuri","year":"2024","unstructured":"Chaudhuri D, Nei AM, Rochwerg B, et al. 2024 focused update: guidelines on use of corticosteroids in Sepsis, acute respiratory distress Syndrome, and Community-Acquired pneumonia. Crit Care Med. 2024;52:e219\u201333.","journal-title":"Crit Care Med"},{"key":"198_CR7","unstructured":"Jones BE, Ramirez JA, Oren E, et al. Diagnosis and management of community-acquired pneumonia: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2025."},{"key":"198_CR8","unstructured":"Angus DC. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia: the REMAP-CAP corticosteroid domain randomized clinical trial. Intensive Care Med. 2025;1\u201316."},{"key":"198_CR9","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00134-022-06684-3","volume":"48","author":"GU Meduri","year":"2022","unstructured":"Meduri GU, Shih M-C, Bridges L, et al. Low-dose Methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022;48:1009\u201323.","journal-title":"Intensive Care Med"},{"key":"198_CR10","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","volume":"388","author":"P-F Dequin","year":"2023","unstructured":"Dequin P-F, Meziani F, Quenot J-P, et al. Hydrocortisone in severe Community-Acquired pneumonia. N Engl J Med. 2023;388:1931\u201341.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"198_CR11","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America\/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27\u201372.","journal-title":"Clin Infect Dis"},{"key":"198_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJM199701233360402","volume":"336","author":"MJ Fine","year":"1997","unstructured":"Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify Low-Risk patients with Community-Acquired pneumonia. N Engl J Med. 1997;336:243\u201350.","journal-title":"N Engl J Med"},{"key":"198_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818\u201329.","journal-title":"Crit Care Med"},{"key":"198_CR14","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559\u201373.","journal-title":"Stat Med"},{"key":"198_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(14)62447-8","volume":"385","author":"CA Blum","year":"2015","unstructured":"Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511\u20138.","journal-title":"Lancet"},{"key":"198_CR16","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(11)60607-7","volume":"377","author":"SCA Meijvis","year":"2011","unstructured":"Meijvis SCA, Hardeman H, Remmelts HHF, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: A randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:2023\u201330.","journal-title":"Lancet"},{"key":"198_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/cid\/cix801","volume":"66","author":"M Briel","year":"2018","unstructured":"Briel M, Spoorenberg SMC, Snijders D, et al. Corticosteroids in patients hospitalized with Community-Acquired pneumonia: systematic review and individual patient data metaanalysis. Clin Infect Dis. 2018;66:346\u201354.","journal-title":"Clin Infect Dis"},{"key":"198_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40635-025-00769-1","volume":"13","author":"JM Smit","year":"2025","unstructured":"Smit JM, Jonkman AH, Krijthe JH. Sub-phenotyping in critical care: a valuable strategy or methodologically fragile path? Intensive Care Med Exp. 2025;13:1\u20133.","journal-title":"Intensive Care Med Exp"},{"key":"198_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1164\/rccm.200406-808OC","volume":"171","author":"M Confalonieri","year":"2005","unstructured":"Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"198_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1164\/rccm.200905-0808OC","volume":"181","author":"D Snijders","year":"2010","unstructured":"Snijders D, Daniels JMA, De Graaff CS, Van Der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: A randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181:975\u201382.","journal-title":"Am J Respir Crit Care Med"},{"key":"198_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.88","volume":"313","author":"A Torres","year":"2015","unstructured":"Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313:677\u201386.","journal-title":"JAMA"},{"key":"198_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.02535-2020","volume":"58","author":"E Wittermans","year":"2021","unstructured":"Wittermans E, Vestjens SMT, Spoorenberg SMC, et al. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: A randomised clinical trial. Eur Respir J. 2021;58:1\u201310.","journal-title":"Eur Respir J"},{"key":"198_CR23","doi-asserted-by":"crossref","unstructured":"Smit JM, Zee PA, Van der Stoof SCM, et al. Predicting individualized treatment effects of corticosteroids in community-acquired pneumonia: a data-driven analysis of randomized controlled trials. MedRxiv. 2023:2023.10.03.23296132.","DOI":"10.1101\/2023.10.03.23296132"},{"key":"198_CR24","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1128\/CVI.00423-12","volume":"19","author":"HHF Remmelts","year":"2012","unstructured":"Remmelts HHF, Meijvis SCA, Biesma DH, et al. Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia. Clin Vaccine Immunol. 2012;19:1532\u20138.","journal-title":"Clin Vaccine Immunol"},{"key":"198_CR25","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/archinte.167.15.1655","volume":"167","author":"JA Kellum","year":"2007","unstructured":"Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study. Arch Intern Med. 2007;167:1655\u201363.","journal-title":"Arch Intern Med"},{"key":"198_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377\u201382.","journal-title":"Thorax"},{"key":"198_CR27","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1097\/CCM.0000000000004093","volume":"48","author":"LE Lansbury","year":"2020","unstructured":"Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and Meta-analysis. Crit Care Med. 2020;48:e98\u2013106.","journal-title":"Crit Care Med"},{"key":"198_CR28","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s00134-018-5332-4","volume":"44","author":"G Moreno","year":"2018","unstructured":"Moreno G, Rodr\u00edguez A, Reyes LF, et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 2018;44:1470\u201382.","journal-title":"Intensive Care Med"},{"key":"198_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/obr.12003","volume":"14","author":"J Choi","year":"2013","unstructured":"Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta\u2010analysis. Obes Rev. 2013;14:232\u201344.","journal-title":"Obes Rev"},{"key":"198_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ejim.2004.07.013","volume":"15","author":"AS Gabriel","year":"2004","unstructured":"Gabriel AS, Martinsson A, Wretlind B, Ahnve S. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med. 2004;15:523\u20138.","journal-title":"Eur J Intern Med"},{"key":"198_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/10408363.2011.599831","volume":"48","author":"KH Allin","year":"2011","unstructured":"Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155\u201370.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"198_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejim.2007.04.026","volume":"19","author":"F Karadag","year":"2008","unstructured":"Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med. 2008;19:104\u20138.","journal-title":"Eur J Intern Med"},{"key":"198_CR33","doi-asserted-by":"publisher","unstructured":"Nasa P, Bos LD, Estenssoro E, et al. Defining and subphenotyping ARDS: insights from an international Delphi expert panel. Lancet Respir Med. 2025. https:\/\/doi.org\/10.1016\/S2213-2600(25)00115-8.","DOI":"10.1016\/S2213-2600(25)00115-8."},{"key":"198_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00134-023-07050-7","volume":"49","author":"G Grasselli","year":"2023","unstructured":"Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023;49:727\u201359.","journal-title":"Intensive Care Med"},{"key":"198_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S2213-2600(25)00054-2","volume":"13","author":"ES Munroe","year":"2025","unstructured":"Munroe ES, Spicer A, Castellvi-Font A, et al. Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill. Lancet Respir Med. 2025;13:556\u201368.","journal-title":"Lancet Respir Med"},{"key":"198_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176\u201386.","journal-title":"Lancet"},{"key":"198_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611\u201320.","journal-title":"Lancet Respir Med"},{"key":"198_CR38","doi-asserted-by":"crossref","unstructured":"Smit JM, Krijthe JH, van Bommel J, et al. The heterogeneous effect of high PEEP strategies on survival in acute respiratory distress syndrome: preliminary results of a data-driven analysis of randomized trials. MedRxiv. 2025:2025.01.23.25320649.","DOI":"10.1183\/13993003.congress-2025.PA994"},{"key":"198_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/cpt.1907","volume":"109","author":"I Bica","year":"2021","unstructured":"Bica I, Alaa AM, Lambert C, van der Schaar M. From Real-World patient data to individualized treatment effects using machine learning: current and future methods to address underlying challenges. Clin Pharmacol Ther. 2021;109:87\u2013100.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Pneumonia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-026-00198-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41479-026-00198-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41479-026-00198-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:56:31Z","timestamp":1781636191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41479-026-00198-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["198"],"URL":"https:\/\/doi.org\/10.1186\/s41479-026-00198-y","relation":{},"ISSN":["2200-6133"],"issn-type":[{"value":"2200-6133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}